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Abstract  
 
Context  Death rattle (Respiratory tract secretion) is a common and potentially distressing symptom in 
dying patients. Health care professionals often struggle with this symptom because of the uncertainty 
about management. 
Objectives To give an overview of current evidence on the prevalence of death rattle in dying patients, its 
impact on patients, relatives and professional caregivers, and the effectiveness of interventions. 
Methods We systematically searched PubMed, EMBASE, CINAHL, PsychInfo and Web of Science. 
English-language papers containing original data on prevalence or impact of death rattle, or on the effects 
of interventions were included.  
Results We included 39 papers, of which 29 reported on the prevalence of death rattle, 8 on its impact, 
and 11 on the effectiveness of interventions. There is a wide variation in reported prevalence rates (12-
92%, weighted mean 35%). Death rattle leads to distress in both relatives and professional caregivers, 
but its impact on patients is unclear. Different medication-regimes have been studied, i.e. scopolamine, 
glycopyrronium, hyoscine butylbromide, atropine and/or octreotide. Only one study used a placebo group. 
There is no evidence that the use of any anti-muscarinic drug is superior to no treatment.  
Conclusions Death rattle is a rather common symptom in dying patients, but it is doubtful if patients 
suffer from this symptom. Current literature does not support the standard use of anti-muscarinic drugs in 
the treatment of death rattle.  
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Introduction 
Care for the dying has received growing attention over the past decade, in both health care research and 
practice. Although several challenges of performing research in end-of-life care have been reported
1-5
, the 
demand for evidence-based guidelines is increasing. Until now, for many symptoms associated with the 
dying phase research has been scarce, as is the case for death rattle. Death rattle (Respiratory tract 
secretion) is a common symptom in dying patients, although reported prevalences vary considerably
6-10
. 
Death rattle is thought to be caused by an accumulation of secretions in the airways
11
. It is unclear 
whether or to what extent it represents discomfort for the patient, and whether nursing and medical 
interventions to reduce its prevalence are needed or effective. Even when the patient does not appear to 
be disturbed by the symptom, treatment is often initiated because of distress in the attending relatives
12-14
. 
Treatment modalities include nursing interventions, e.g. repositioning of the patient and suction of 
secretions and pharmacological interventions. Use of anti-muscarinic drugs is recommended in several 
palliative care textbooks
11, 15-18
.  
A recent Cochrane review focusing on interventions for death rattle concluded that there is no evidence 
that any intervention, pharmacological or non-pharmacological, was superior to placebo in the treatment 
of noisy breathing in dying patients
19
. This Cochrane review was based on 4 papers (two English, two 
German) and only included level A evidence studies, i.e. randomized controlled trials and high-quality 
prospective controlled studies. Randomized controlled trials among patients who are in the dying phase 
are rare, mainly because of ethical and practical considerations related to randomization, informed 
consent, use of placebo and follow-up
1-5
. Studies with a lower level of evidence can also provide useful 
information on care for dying patients. We performed a systematic search of the scientific literature with 
the aim of giving a comprehensive overview of empirical studies on the prevalence of death rattle, its 
impact on patients, relatives and professional caregivers, and the effectiveness of interventions. 
 
Methods 
We conducted a systematic search of the databases PubMed, EMBASE, CINAHL, Web of Science and 
PsychInfo. All databases were searched for papers published up to August 2012 in English on the 
prevalence, impact and treatment of death rattle. For a detailed overview of the search strategy, see 
figure 1. The search strategy was not restricted to recent publications to retrieve all the relevant literature. 
In addition, we hand-searched reference lists of included papers and relevant literature reviews.  
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Study selection  
Studies were included when they met the following inclusion criteria: the study described original 
empirical research about death rattle in the dying phase of human adults; the study included data about 
the prevalence of death rattle, experiences of patients, relatives or professional caregivers with death 
rattle, or the effectiveness of interventions. Studies on the prevalence of death rattle had to include at 
least 50 persons. Reviews, comments, case studies, letters and conference abstracts were excluded.  
All duplicates were removed. Papers were selected in a stepwise procedure. First, all papers’ titles were 
assessed as possibly relevant or not relevant, titles that were not relevant were excluded.. In the second 
step, the abstracts of the remaining papers were screened on the selection criteria. If the abstracts met 
these criteria, papers were assessed full text in step 3.  
 
Titles of 10% of the papers were independently assessed by two reviewers (MEL and AvdH). Cohen’s 
Kappa was calculated to determine the level of agreement: κ=0·78, indicating a substantial agreement
20
. 
Differences in scoring were discussed until consensus was reached. The remaining titles were assessed 
by MEL. This procedure was repeated for the assessment of abstracts (κ=0·77) and full texts (κ=0·90). Of 
all the studies that did not pass the selection process, the reasons for non-inclusion were registered.  
 
Data extraction  
We collected information on general characteristics of the studies and results related to our research 
questions, using a standardized extraction form. Extracted data included the number of patients studied, 
study setting, study design, source of information, frequency of measurements, measurement method, 
primary diagnosis (cancer or non-cancer), and general patient characteristics. Further, we extracted data 
on the prevalence of death rattle, assessments of the impact of death rattle on patients, relatives and 
professional caregivers, and effects of medical and non-medical interventions.  
 
Quality assessment  
The quality of the selected studies was assessed using the multi-methods assessment tool, devised by 
Hawker et al
21
. This tool can be used to evaluate studies with quantitative and qualitative designs. All 
studies were assessed on nine different aspects: abstract and title; introduction and aims; method and 
data; sampling; data analysis; ethics and bias; results; transferability or generalizability; and implications 
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and usefulness. Per area a score was given on a four-point scale, from 1 = very poor to 4 = good. 
Summing up the different area scores results in a total score, from 9 = very poor to 36 = good. 
 
Results  
Selection of papers 
Our search yielded 1062 unique papers. In the first step, 824 papers were excluded because the paper’s 
titles were assessed as not relevant. In the second step, 84 papers were excluded because their abstract 
did not meet the selection criteria. This resulted in 154 remaining papers of which 36 could be included 
after assessment of the full-texts (Figure 1). A manual search of references identified three other studies, 
making a total of 39 studies (Table 1). 
The studies were published between 1988 and 2012. Eight studies were performed in Asia, of which 
seven in Japan; two in Australia; one in New Zealand; 24 in Europe, of which 16 in the United Kingdom; 
and four in North America. The 39 studies included three randomized controlled trails
22-24
, two prospective 
comparative studies
25-26
, eight prospective observational studies
7-8, 10, 27-31
, two cross sectional surveys
32-
33
, two retrospective surveys
34-35
, 18 medical record reviews
6, 9, 36-51
, three qualitative interview studies
12, 
14, 52
, and one qualitative focus group study
13
. 
 
Quality assessment 
The total scores for quality of the included papers are presented in Table 1. One article was rated 
between ‘‘very poor’’ and ‘‘poor;’’ 20 articles were rated between ‘‘poor’’ and ‘‘fair;’’ and 18 articles were 
rated between ‘‘fair’’ and ‘‘good.’’ 
 
Labels and definitions of death rattle 
Various labels were used to describe death rattle: bronchial secretion, (troubling/noisy/terminal) 
respiratory (tract) secretions, increasing secretions, noisy retained secretions, terminal secretions, 
pulmonary rattles, noisy (rattling/moist) breathing (at the end of life), or respiratory symptoms. In addition, 
definitions of death rattle varied between studies. Twenty-two papers provided a definition of death rattle. 
Elements included in these definitions were: the noise or sound associated with death rattle
6-9, 12-14, 22-26, 28-
31, 33, 41, 43, 50-52
, the movement of (accumulated) secretions
7-9, 22-23, 28-31, 41, 43, 50-51
, location in the 
hypopharynx or bronchial tree
7-8, 25, 28-31, 41, 43, 51
 or upper airways
9, 23, 50
, the relation with respiration
6-9, 12-14, 
22-23, 25, 28-31, 33, 41, 43, 50, 52
, its occurrence in the terminal phase of an illness
6, 9, 12, 14, 22-23, 25, 41
, its relation with 
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weakness and/or inability to cough or clear the airways
6, 9, 22-23, 25, 51
, the idea that it can be distressing for 
those involved
6, 8, 22, 25, 41, 50-51
. 
 
Prevalence of death rattle 
Data on the prevalence of death rattle were reported in 29 papers (table 2). Sample sizes ranged 
between 68-2382 patients. Studies were performed in hospitals (34%), palliative care units (45%), home 
care (28%), hospices (34%) or long term care facilities (7%), some studies concerned more than one type 
of setting. Sixteen studies were performed in a population of patients with a diagnosis of primary cancer, 
eight in a mixed population (cancer and non-cancer combined) and in five studies the diagnosis of 
patients was not specified.  
 
The prevalence of death rattle varied between studies. The lowest and highest percentages reported 
were 12%, in a retrospective study of 169 patients with a brain tumor
45
, and 92%, in a prospective study 
of 82 patients with various forms of cancer, respectively
7
. The weighted mean for these 29 studies was 
35% The reported median time from the onset of death rattle until death was between 11-28 hours
23-25, 30, 
41, 43, 51
.  
Six studies
23-25, 27-29
 used a scoring scale as proposed by Back et al.
25
 to assess the severity of death 
rattle. This scoring scale records the volume of noise associated with death rattle: 0, inaudible; 1, audible 
only very close to the patient; 2, clearly audible at the end of the bed, in a quiet room; 3, clearly audible at 
about 20 ft (9.5 m) (at the door of the room), in a quiet room. Of these six studies, four presented data 
about the severity of death rattle: 6-17% of all patients had death rattle score 1, 19-26% had score 2 and 
5-11% had score 3
23-25, 28
. 
Patient characteristics that were found to be significantly associated with the presence of death rattle 
were a disoriented cognitive function
42
, male gender
43
, lung cancer
8, 28, 43
, a tumor located in bone, liver, 
intestinal tract
8
 or brain
6, 8
 , pneumonia
28
 and a duration of stay in a hospice of more than nine days
6
 (see 
appendix).  
 
Impact of death rattle 
Data on the impact of death rattle on patients, relatives and professional caregivers were reported in eight 
studies: four quantitative studies
32-34, 44
 and four qualitative studies
12-14, 52
 (table 3). Sample sizes in the 
four quantitative studies ranged between 11-65 respondents. Respondents were nurses
32-33, 44
 or 
bereaved relatives
34
. Sample sizes in the four qualitative studies ranged between 12-41 respondents. 
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Respondents were professional or informal caregivers (nurses, physicians and volunteers)
13, 52
 or 
bereaved relatives
12, 14
. 
 
Impact on patients 
In a study among nurses, 87% indicated that they felt that death rattle does not distress the dying 
patient
32
. A qualitative study among physicians, nurses and volunteers suggested that patients may feel 
distressed because of the sound of death rattle of other patients in the same ward
13
. 
 
Impact on relatives 
Eight studies provided information on the impact of death rattle on relatives. According to one study, 
relatives perceived death rattle as ‘not so distressing’ in 5%, as ‘slightly distressing’ in 15%, as 
‘distressing’ in 26%, and as ‘very distressing’ in 52%
34
. In two studies among nurses, 100% of them 
indicated that death rattle causes distress for all those involved, but particularly for relatives
32-33
. Such 
distress is, according to one study among nurses, related to relatives experiencing that patients were 
‘gagging’ and ‘drowning’ in secretions (no percentage mentioned)
44
.  
The qualitative studies suggested that, although death rattle was regarded as distressing for most 
relatives
12-14, 52
, some relatives found it reassuring to hear the patient breathe, or regarded death rattle as 
a helpful warning sign of impending death
12, 14, 52
.  
 
Impact on professional caregivers 
One quantitative and two qualitative studies reported on the impact of death rattle on professional 
caregivers. In a cross-sectional survey, 79% of nurses regarded death rattle as distressing
32
. Focus 
groups with hospice staff and volunteers and interviews with physicians and nurses showed that for them, 
death rattle may be distressing
13, 52
. Interviewed nurses and physicians mentioned that they themselves 
possibly benefited from interventions to diminish death rattle. This benefit is related to being able to do 
something for the patient and family
52
. 
 
Interventions for death rattle 
Eleven studies reported on the effectiveness of interventions for death rattle (table 4). Sample sizes 
ranged between 5-167 respondents per study group. Nine studies described medical interventions and 
two studies described the association between the hydration level and death rattle. No studies were found 
on the effectiveness of other interventions, e.g. repositioning of the patient, explanation of the symptom to 
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relatives, or suctioning of secretions. Eight studies had a comparative design, comparing two or three 
interventions
22-27, 29, 41
. Three studies were not controlled
9, 43, 51
.  
Six studies compared two or three medication-regimes. Medications studied included scopolamine
22-23, 25-
26, 41
, glycopyrronium
25-26, 41
, hyoscine butylbromide
23, 26
, atropine
23-24
 and octreotide
22
. Three studies found 
no differences in the effectiveness of the different medication regimes
22-23, 26
.  One randomized controlled 
trail found no differences in the prevalence of death rattle between patients receiving atropine and 
patients receiving a placebo
24
. One comparative but uncontrolled study found that scopolamine was 
significantly more effective than glycopyrronium in reducing the severity of death rattle as recorded by 
nurses 30 minutes after administration of the medication, but no difference was found one hour after 
administration and at the final measurement before death
25
. A retrospective study using medical records 
found contrasting results: patients who received glycopyrronium were significantly more often reported as 
having a response to treatment than patients receiving scopolamine
41
.Two studies compared two groups 
with different hydration regimes (<1 liter/ day versus ≥1 liter/day)
27, 29
. A reduced level of hydration was 
found not to change death rattle prevalence. 
 
Discussion  
The prevalence of death rattle was found to vary widely. Several characteristics of studies that assessed 
prevalences may explain this variance. First, there is a wide variety of labels and definitions used to 
describe death rattle, with the noise or sound as a constant element in all definitions. Whether the various 
labels all represent the exact same phenomenon is however not clear. Second, different study designs 
were used: 34% were prospective studies, 64% were retrospective studies. The weighted mean for the 
prevalence of death rattle in the prospective studies was 45%, compared to 30% in the retrospective 
studies. Third, few studies reported the exact point in time during the dying process at which the presence 
of death rattle was assessed. The natural course of death rattle is not clear. Kass and Ellershaw suggest 
that the prevalence of death rattle typically increases when death approaches
43
. However Heisler et al. 
performed a placebo controlled trial and found an decrease of death rattle scores over time in the placebo 
group
24
. Fourth, studies reporting on prevalences were often restricted to patients with cancer, but some 
studies also included non-cancer patients. Whether specific diseases are associated with the prevalence 
of death rattle is unclear. Only patients with cerebral or lung malignancies were found to have a higher 
risk of death rattle
6, 8, 28, 43
. More studies are needed to give insight into specific relationships between 
underlying disease and death rattle prevalence rate. Fifth, measurement methods to determine death 
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rattle prevalence varied between the different studies. Validated instruments, such as the death rattle 
scoring scale
25
 were not used by most studies. 
 
The impact of death rattle on patients remains unclear and can only be based on subjective reports of 
others. It is often assumed by health care professional that patients are not distressed by this symptom, 
because they are generally unconscious when death rattle develops. Many professional caregivers 
assume that death rattle is distressing for relatives
13
. Whether relatives experience distress seems to be 
related to their judgment whether a patient is comfortable. For some relatives the symptom can also have 
a helpful meaning, either through helping relatives realizing that the patient is still alive, or by seeing  it as 
a sign of impending death. Professional caregivers themselves may also be distressed by the noise of 
death rattle, which often results in a medical intervention. Wee et al.
13
 and Heisler et al.
24
 suggest that the 
way in which professional caregivers interpret the symptom can influence their response and actions, 
which could also affect relatives’ perceptions. Professional caregivers should be aware of this effect. 
 
A number of different interventions for the treatment of death rattle are included in guidelines and 
palliative care textbooks: repositioning of the patient, explanation of the symptom to relatives, suctioning 
of secretions, diminishing artificial hydration, administration of anti-muscarinic drugs and sedation. Only 
reducing the level of hydration and treatment with anti-muscarinic drugs have been studied for their 
effectiveness. Two studies among patients with abdominal cancer found no relation between the level of 
hydration and the prevalence of death rattle. There is no evidence that the use of any anti-muscarinic 
drug is superior to no treatment. This finding is in line with the previous Cochrane review focusing on 
interventions for death rattle
19
. However, studies on the effect of pharmacological interventions are limited 
by their lack of a placebo group. Well designed studies to assess the relation between hydration and 
death rattle, as well as studies on the effects of non-pharmacological interventions for death rattle are still 
lacking. More prospective randomized controlled studies on the effectiveness of medical therapy and 
other interventions are urgently needed to confirm these findings. 
 
We conclude that death rattle is a common symptom in dying patients. Approximately a third of the  
patients will present with this symptom during the dying process. Current evidence does not support the 
standard use of anti-muscarinic drugs in the treatment of this symptom. More high quality studies are 
needed to give insight in the effects of interventions, both pharmacological and non-pharmacological. 
Until then, care should focus on communication about the symptom with relatives and others involved in 
10 
 
the care of these patients. Regarding the symptom as being part of the normal dying process could 
contribute to the lowering of distress levels of those involved. 
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Table 1 General characteristics of included studies (n=39) 
 Author/country 
Year of 
publication  
                            
Setting Sample size Design 
Quality 
assessment
a 
Asia 
 Yamaguchi et al.,
27
, Japan 2012 Hospital, PCU, home care 161 Prospective observational study 28 
 Morita et al
29
., Japan 2005 Hospital, PCU, home care  226 Prospective observational study 29 
 Seah et al
48
., Singapore 2005 Hospital 189 Medical records review 27 
 Morita et al
28
., Japan 2004 Hospital, PCU, home care  310 Prospective observational study 29 
 Morita et al
34
., Japan 2004 PCU 195 Retrospective survey  20 
 Morita et al
8
., Japan 2000 Hospital  245 Prospective observational study 26 
 Morita et al
31
., Japan 1999 Hospice 350 Prospective observational study 26 
 Morita et al
30
., Japan 1998 Hospice 100 Prospective observational study 23 
Australia 
 Sheehan et al
50
, Australia 2011 PCU 199 Medical records review 28 
 Clark et al
22
., Australia 2008  Hospital  10 Randomized controlled trail 29 
 Lichter et al.
10
, New Zealand 1990 Hospice 200 Prospective observational study 21 
Europe 
 Lundquist et al
49
, Sweden 2011 Hospital, home-care, PCU, 
residential care 
2382 Medical records review 31 
 Mercadante et al
35
, Italy 2011 Home-care 181 Retrospective survey  29 
 Bradley et al
52
., UK 2010 Hospital, hospice  15  Qualitative interviews  29 
 Pace et al
45
., Italy 2009 Home-care 169 Medical records review 23 
 Wildiers et al
23
., Belgium 2009 PCU 333 Randomized controlled trail 32 
 Jakobsson et al
42
., Sweden 2008 Residential care, home care 229 Medical records review 30 
 Wee et al
13
., UK 2008 Hospice 41 Qualitative focus groups  27 
 Wee et al
12
., UK 2006 Hospital, hospice, home care 12  Qualitative interviews  31 
 Wee et al
14
., UK 2006 Hospital, hospice, home care 17  Qualitative interviews  30 
 Hugel et al
41
., UK 2006  PCU 165 Medical records review 25 
 Grogan et al
38
., UK 2005 Hospice/ PCU 68 Medical records review 21 
 Kass et al
43
., UK 2003 PCU 202 Medical records review 26 
 Fowell et al
37
., UK 2002 Hospital, hospice, PCU,  
home care 
500 Medical records review 28 
 Wildiers et al
9
., Belgium 2002 Hospital  107 Medical records review 20 
 Back et al
25
., UK 2001 PCU 504 Prospective comparative study 26 
 Ellershaw et al
36
., UK 2001 PCU 168 Medical records review 25 
 Hughes et al
26
., UK 2000 Hospice, PCU 111 Prospective comparative study 20 
 Watts et al
32
., UK 1999 Not specified 23  Cross sectional survey  17 
 Pautex et al
46
., Switserland 1997 Hospital  100 Medical records review 20 
 Watts et al
33
., UK 1997 PCU 23 Cross sectional survey  23 
 Bennett et al
6
., UK 1996 Hospice 96 Medical records review 22 
 Ellershaw et al
7
., UK 1995 Hospice 82 Prospective observational study 28 
 Power et al
47
., Ireland 1992 Hospice  100 Medical records review 19 
 Hoskin et al
40
., UK 1988 Hospital  158 Medical records review 20 
North-America 
 Heisler et al
24
, USA 2012 PCU 137 Randomized controlled trail 31 
 Protus et al
51
, USA 2012 Hospice 147 Medical records review 23 
 Hall et al
39
., Canada 2002 Long term care facilities 185 Medical records review 27 
 Lindley-Davis et al
44
., USA 1991 Home care  11 Medical records review 24 
 
Abbreviations: PCU= palliative care unit  
a) Quality assessment: 9 = very poor, 18 = poor, 27 = fair, 36 = good. 
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Table 2 Studies reporting on prevalence of death rattle (n=29)  
 
Author/country/year 
    
Prevalence  Setting
 
Symptom label Measurement method Design Sample size
a 
Diagnosis
 
 Pace et al.
45
 
Italy, 2009 
Home care Death rattle Death rattle presence as listed in medical record Retrospective 169  Cancer (brain tumors) 12% 
 Seah et al.
48
 
Singapore, 2005 
Hospital Troubling respiratory 
secretions 
Death rattle presence as listed in medical record Retrospective 189  Mixed (cancer and various 
non-cancer) 
15% 
 Mercadante et al.
35
 
Italy, 2011 
Home care Death rattle Death rattle presence during last two hours of 
patient’s life as determined by relatives 
Retrospective 181  Cancer (various tumors) 16% 
 Lundquist et al.
49
 
Sweden, 2011 
Hospital, PCU, 
home care,  
residential care 
Respiratory tract 
secretions 
Death rattle presence as listed in medical record Retrospective 238
2 
 Cancer (various tumors) 17% 
 Wildiers et al.
9
 
Belgium, 2002 
Hospital  Death rattle Death rattle presence as listed in medical record Retrospective 107  Cancer (various tumors) 23% 
 Protus et al.
51
 
USA, 2012 
Hospice Terminal respiratory 
secretions 
Death rattle presence as listed in medical record Retrospective 147  Mixed (cancer and various 
non-cancer) 
27% 
 Jakobsson et al.
42
 
Sweden, 2008 
Residential care, 
home care 
Pulmonary rattles Death rattle presence as listed in medical record Retrospective 229  Diagnosis not specified 30% 
 Morita et al.
34
 
Japan, 2004 
PCU Bronchial secretion Death rattle frequency during last week of 
patient’s life as rated by relatives:  
 ‘not at all,’ ‘sometimes,’ ‘often,’ ‘very often.’ Prevalence 
based on grouping together ‘often’ and ‘very often’ 
Retrospective 195  Cancer (not specified) 33% 
 Hoskin et al.
40
 
UK, 1988 
Hospital  Respiratory 
symptoms 
Death rattle presence based on anti-muscarinic 
drugs use as listed in medical record 
Retrospective 158  Cancer (various tumors) 34% 
 Morita et al.
30
 
Japan, 1998 
Hospice Death rattle Death rattle presence observed by professional 
caregivers 
Prospective 100  Cancer (various tumors) 35% 
 Pautex et al.
46
 
Switserland, 1997 
Hospital  Death rattle Death rattle presence as listed in medical record Retrospective 100  Mixed (cancer and various 
non-cancer) 
38% 
 Hall et al.
39
 
Canada, 2002 
Hospice Noisy breathing Death rattle presence as listed in medical record Retrospective 185  Mixed (cancer and various 
non-cancer) 
39% 
 Morita et al.
28
 
Japan, 2004 
Hospital, PCU,  
home care  
Bronchial secretion Death rattle scoring scale Back et al.
25
 Prospective 310  Cancer (lung/abdominal) 41% 
 Back et al.
25
 
UK, 2001 
PCU Death rattle Death rattle scoring scale Back et al.
25
 Prospective 504  Cancer (various tumors) 41% 
 Yamaguchi et al.
27
 
Japan, 2012 
Hospital, PCU,  
home care 
Bronchial secretion Death rattle scoring scale Back et al.
25
 Prospective 151  Cancer (abdominal) 43% 
Abbreviations:  PCU = Palliative care unit   
a) Number of patients in the study on which prevalence was based 
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Table 2 Studies reporting on prevalence of death rattle (continued) 
 
Author/country/year 
    
Prevalence  Setting
 
Symptom label Measurement method Design Sample size
a 
Diagnosis
 
 Heisler et al.
24
 
USA, 2012 
PCU Death rattle Death rattle scoring scale Back et al.
25
 Prospective 404  Mixed (cancer and various  
non-cancer) 
44% 
 Morita et al.
8
 
Japan, 2000 
Hospital  Death rattle Death rattle presence as observed by 
professional caregivers 
Prospective 245  Cancer (various tumors) 44% 
 Morita et al.
31
 
Japan, 1999 
Hospice Death rattle Death rattle presence as observed by 
professional caregivers 
Prospective 350  Cancer (various tumors) 44% 
 Power et al.
47
 
Ireland, 1992 
Hospice  Respiratory 
secretions 
Death rattle presence based on use of anti-
muscarinic drugs as listed in medical record 
Retrospective 100  Diagnosis not specified 44% 
 Morita et al.
29
 
Japan, 2005 
Hospital, PCU, 
home care  
Bronchial secretion Death rattle scoring scale Back et al.
25
 Prospective 226  Cancer (abdominal) 45% 
 Ellershaw et al.
36
 
UK, 2001 
PCU Respiratory tract 
secretion 
Death rattle presence as listed in medical record Retrospective 168  Diagnosis not specified 45% 
 Bennett et al.
6
 
UK, 1996 
Hospice Death rattle Death rattle presence as listed in medical record Retrospective 96  Mixed (cancer and various  
non-cancer) 
45% 
 Kass et al.
43
 
UK, 2003 
PCU Respiratory tract 
secretions 
Death rattle presence as listed in medical record Retrospective 202  Cancer (various tumors) 49% 
 Fowell et al.
37
 
UK, 2002 
Hospital, hospice, 
PCU, home care 
Respiratory tract 
secretions 
Death rattle presence as listed in medical record Retrospective 500  Mixed (cancer and various  
non-cancer) 
50% 
 Lichter et al.
10
 
New Zealand, 1990 
Hospice Noisy and moist 
breathing 
Death rattle presence as observed by 
professional caregivers 
Prospective 200  Diagnosis not specified 56% 
 Grogan et al.
38
 
UK, 2005 
Hospice, PCU Respiratory 
secretions 
Death rattle presence as listed in medical record Retrospective 68  Diagnosis not specified 59% 
 Sheehan et al.
50
, 
Australia, 2011 
PCU Noisy respiratory 
secretions 
Death rattle presence based on anti-muscarinic 
drugs use as listed in medical record 
Retrospective 199  Mixed (cancer and various  
non-cancer) 
60% 
 Hugel et al.
41
 
UK, 2006 
PCU Respiratory tract 
secretions 
Death rattle presence as listed in medical record Retrospective 165  Cancer (various tumors) 80% 
 Ellershaw et al.
7
 
UK, 1995 
Hospice Respiratory tract 
secretion 
Death rattle presence observed by professional 
caregivers or anti-muscarinic drug administered 
Prospective 82  Cancer (various tumors) 92% 
Abbreviations:  PCU = Palliative care unit   
a)  Number of patients in the study on which prevalence was based 
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Table 3 Studies reporting on impact of death rattle (n=8) 
 Author/country 
Year of 
publication  
                          
Setting 
 
Design Source
 
Sample size
a
  Description of impact  
Quantitative studies 
 Morita et al
34
., 
Japan 
2004 PCU 
 
Retrospective 
survey of relatives 
Relatives of patient 
with death rattle 
65  Impact (of death rattle) on relatives  
Relatives’ reports on the impact of death rattle: ‘not distressed at all’ (n=0 / 0%), 
‘not so distressed’ (n=3 / 5%), ‘slightly distressed’ (n=10 / 15%), ‘distressed’  
(n= 17 / 26%), or ‘very distressed’ (n= 34 / 52%). 
 Watts et al
32
., UK 1999 Not specified 
 
 
Cross sectional 
survey of nurses 
Nurses  23   Impact (of death rattle) on patients 
Death rattle does not distress the dying person (n=30 / 87%)  
Impact (of death rattle) on relatives 
Death rattle distresses relatives (n=23 / 100%). 
Relatives mention to nurse that the death rattle in particular had caused  
them distress (n=12 / 52%)  
Impact (of death rattle) on caregivers 
Death rattle distresses nurses (n=18 / 79%), some thought that suction is 
appropriate (n=6 / 26%) 
 Watts et al
33
., UK 1997 PCU 
 
Cross sectional 
survey of nurses 
Nurses  23  Impact (of death rattle) on relatives 
Death rattle causes distress to all parties, but particularly to relatives 
(n=23/100%) 
 Lindley-Davis et 
al
44
., USA 
1991 Home care 
 
Medical records 
review 
Nurses 11  Impact (of death rattle) on relatives 
Relatives’ distress with death rattle: Relatives had high levels of anxiety as  
the client began ‘gagging’ and ‘drowning’ in secretions. (n=not mentioned in 
article).  
Qualitative studies 
 Bradley et al
52
., 
UK 
2010 Hospital, hospice  
 
 
Qualitative 
interviews with 
physicians and 
nurses 
Physicians and 
  nurses 
15   Impact (of death rattle) on relatives 
Death rattle can cause family distress. Some families find a positive side to 
the presence of death rattle (it gives them reassurance to hear them breathe). 
Respondents believe that families may benefit from their management 
choices. 
Impact (of death rattle) on caregivers 
Nurses and other staff are likely to be distressed by death rattle; some 
respondents suggest that death rattle has little to no impact. The impact is 
described as feeling uncomfortable, feeling frustrated or unpleasant, or as 
death rattle being distressing or hard to bear.  
Caregivers may benefit from management decisions, because doing 
something feels more comfortable than doing nothing  
Abbreviations: PCU= palliative care unit 
a) persons in the study that reported on impact of death rattle 
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Table 3 Studies reporting on impact of death rattle (continued) 
 Author/country 
Year of 
publication  
                          
Setting 
              
Design Source
 
Sample size 
a 
Description of impact  
 Wee et al
13
., UK 2008 Hospice 
 
Qualitative focus 
groups with staff 
and volunteers 
Physicians, nurses 
and volunteers 
41  Impact on patients 
Patients in the same ward may feel distressed because of the sound of death 
rattle of other patients. 
Impact (of death rattle) on relatives 
Death rattle is believed to distress relatives.  
Impact (of death rattle) on caregivers 
Hospice staff and volunteers have largely negative feelings about death rattle. 
Doctors and nurses were divided about why they intervened  
The way in which they themselves make sense of the sound influences both 
their response to relatives and the actions they take. 
 Wee et al
12
., UK 2006 Hospital, hospice, 
home care 
 
Qualitative 
interviews  
Relatives of patient 
with death rattle 
12   Impact (of death rattle) on relatives 
Some have explicit negative feelings about the sound of death rattle. This was 
sometimes associated with their concerns about the patient’s suffering. Others 
are not distressed; some even found it helpful, as a warning sign of impending 
death. 
 
 
Wee et al
14
., UK 2006 Hospital, hospice, 
home care 
 
Qualitative 
interviews  
Relatives of patient 
with death rattle 
17   Impact (of death rattle) on relatives 
Most are distressed by the sound of death rattle. Others are not particularly 
bothered, regard it as a useful warning sign that death was imminent or are 
more distressed by other issues surrounding the dying process.  
Relatives may take their cue from the patient’s appearance, being concerned 
if the patient looks distressed, but less so if the patient is not obviously 
disturbed.  
Abbreviations: PCU= palliative care unit 
a) persons in the study that reported on impact of death rattle 
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Table 4 Studies reporting on interventions for death rattle and their effectiveness (n=11) 
 
Author / county / 
year/ design 
   Interventions for death rattle 
 
Setting Diagnosis Description of intervention 
a
  Outcome measure Effectiveness of intervention  
Two or more study groups (medication) 
 Heisler et al.
24
 
USA, 2012 
Randomized 
controlled trail 
PCU Mixed  
(cancer & various 
non-cancer) 
1) Atropine (n=74) 
1 mg sublingually (2 drops 1% solution) 
2) Placebo (n=63) 
2 drops of placebo (saline) solution 
Reduction of score with ≥ 1 point 
Death rattle score Back et al
25
  
No difference between groups 
Effectiveness after two hours;  
38%, 41% (p = 0·73) 
Effectiveness after four hours;  
40%, 52% (p = 0·21) 
 
 Wildiers et al.
23
 
Belgium, 2009 
Randomized 
controlled trail 
PCU Cancer  
(various tumors) 
1) Atropine (n=115)  
   0,5 mg sc bolus, followed by 3 mg/24h  
2) Scopolamine (n=112) 
   0,25 mg sc bolus, followed by 1,5mg/24h 
3) Hyoscine butylbromide (n=106)  
   20 mg sc bolus, followed by 60 mg/24h 
Lowering of score to 0 or 1  
Death rattle score Back et al
25
  
No difference between groups 
Effectiveness after one hour;  
42%, 37%, 42% (p = 0·72) 
Effectiveness after 24 hours; ;  
76%, 68%, 60% (ns; p unknown) 
 
 
 Clark et al.
22
 
Australia, 2008 
Randomized 
controlled trail 
 Hospital  Cancer  
(various tumors) 
1) Octreotide (n=5) 
   0,2 mg bolus , if death rattle persisted ≥ 1h 
   0,4 mg Scopolamine was administered 
2) Scopolamine (n=5)  
   0,4 mg bolus, if death rattle persisted ≥ 1h    
   0,2 mg Octreotide was administered  
 
A decrease in the level of death rattle 
Level categorized into 5 points: none, mild, 
moderate, severe, very severe 
No difference between groups 
Overall effectiveness; 40%, 40% 
 Back et al.
25
 
UK, 2001 
Prospective 
comparative study 
PCU Cancer 
(various tumors) 
1) Scopolamine (n=108)  
   0,4 mg sc bolus, if the noise was still  
   unacceptable ≥30 min. 0,4 mg sc repeated. 
   Optionally followed by 1,2 – 2,4 mg/ 24 h sc  
 2) Glycopyrronium (n=62)  
   0,2 mg sc bolus, if the noise was still  
   unacceptable ≥30 min 0,2 mg sc repeated.  
   Optionally followed by 0,8 mg/ 24h sc   
  
Death rattle scores at 30 min, 1 h and 
final score before death were 
compared with the initial score, and 
categorized as better, the same or 
worse. 
Death rattle score Back et al
25
  
Scopolamine group responded more 
often than Glycopyrronium group  
(p = 0·002) at t= 30 minutes 
Effectiveness after 30 min; 56%, 27% (p = 0·002)  
Effectiveness after one hour; 57%, 40% (p=0·09)  
Symptom-free at death; 51%, 42% (p=0·12) 
 Hughes et al.
26
. 
UK, 2000 
Prospective 
comparative study 
Hospice, 
PCU, 
hospice 
Diagnosis not 
specified 
1) Scopolamine (n=37) 
   0,4 mg bolus, after 30 min with no result  
   0,6 mg bolus and 2,4 mg/ 24h 
   after 30 min with no result 0,6 mg scopolamine # 
2) Hyoscine butylbromide (n=37) 
  20 mg bolus, after 30 min with no result  
   20 mg bolus and 20 mg/24h 
   after 30 min with no result 0,2 mg glycopyrronium # 
3) Glycopyrronium (n=37)  
  0,2 mg bolus, after 30 min with no result  
   0,4 mg bolus and 0,6 mg/24h 
   after 30 min with no result 0,4 mg glycopyrronium #  
Level of relief of death rattle noise and 
of relatives’ distress.  
Baseline levels 
 Intensity of death rattle noise: 
mild, moderate or severe 
 Relatives’ distress:  
not at all, a little, quite a bit, very much  
 
Level of change 
 Absent, much better, slightly better, 
same, slightly worse or much worse 
No difference between groups 
Effectiveness after 30 min; 35%, 54%, 46%  
(p unknown) 
Symptom-free at death; 54%, 65%, 65% (ns; p 
unknown) 
 
 
 
Abbreviations sc= subcutaneous p.r.n.=pro re nata (as needed medication) 
#)  treatment schedule continued: after 30 min with no result 0,4 mg glycopyrronium, after 30 min with no result 0,4 mg glycopyrronium 
a)  n= number of patients in the intervention group 
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Table 4 Studies reporting on interventions for death rattle (continued) 
 
Author / county / 
year/ design 
  Interventions for death rattle 
                 
Setting Diagnosis Description of intervention 
a
 Outcome measure Effectiveness of intervention 
Two or more study groups (medication) 
 Hugel et al
41
.,  
UK, 2006 
Medical records 
review 
PCU Cancer  
(various tumors) 
1) Glycopyrronium (n=36)  
   0,2 mg sc bolus, followed by 0,6mg/24h 
   (+ p.r.n. 0,2 mg). ≥2 p.r.n. doses/24h   
   =>continuous dose increase to 1,2mg/24h  
2) Scopolamine (n=36)  
   0,4 mg sc bolus, followed by 1,2mg/24h  
   (+ p.r.n. 0,4 mg) ≥2 p.r.n. doses/24h =>  
   continuous dose increased to 2,4 mg/24h 
Response was determined grouping 
together immediate, late, and 
transient response, and comparing it 
to no response  
 
Response categorized $ 
 
Glycopyrronium group responded more 
often than scopolamine group (p = 
0·01)  
Overall response: 
group 1) 100%, group 2) 78% (p = 0·01) 
Symptom-free at death: 
group 1 72%, group 2 58% (p unknown) 
Two or more study groups (non-medication) 
 Morita et al.
29
 Japan, 
2005 
Prospective 
observational study 
Hospital, 
PCU 
home care 
Cancer 
(abdominal) 
1) Hydration group (n=59) 
   ≥ 1 l/day at 1 week & 3 weeks before death 
2) Non-hydration group (n=167) 
   < 1 l/day at 1 week & 3 weeks before death 
 
Symptom severity in the last 3 weeks 
of the patients with and without 
hydration 
Death rattle score Back et al
25
  
No difference between groups 
Difference in death rattle score ≥ 1 (p = 0·79) 
Difference in death rattle score  ≥ 2 (p = 0·74) 
 Yamaguchi et al.
27
 
Japan, 2012 
Prospective 
observational study 
Hospital, 
PCU,  
home care 
Cancer 
(abdominal) 
1) Large volume hydration group (n=80) 
   ≥ 1 l/day at study inclusion 
2) Small volume hydration group (n=56) 
   < 1 l/day at study inclusion 
 
Symptom severity 48 hours before 
death 
Death rattle score Back et al
25
  
No difference between groups 
Difference death rattle prevalence (p = 0·073) 
One group 
 Protus et al.
51
 
 USA, 2012 
Medical records review 
Hospice Mixed  
(cancer & various 
non-cancer) 
1) Atropine (n=22) 
2 drops 1% solution sublingually (0,5mg/drop) every 
2 h as needed 
The reduction or resolution of death 
rattle  
Overall effectiveness; 86% 
 
 Kass et al.
43
 
UK, 2003 
Medical records review 
PCU Cancer  
(various tumors) 
1) Scopolamine (n=59)  
  0,4 mg bolus, followed by 1,2 mg/24h  
   if no result after 24 hours => continuous dose  
   increased to 2,4 mg/24h 
 
The presence or absence of death 
rattle 
Effectiveness within four hours; 31%·  
Overall effectiveness/ symptom-free before 
death; 64% 
 Wildiers et al.
9
 
Belgium, 2002 
Medical records review 
Hospital  Cancer 
(various tumors) 
1) Scopolamine (n=25) 
   0,25 mg/4h bolus or iv dose between 1 - 2,5 mg/24h 
 
Medication was effective when there 
was no evidence for persisting 
disturbing rattle (as well for relatives 
as for the caregivers). 
Overall effectiveness; 72% 
 
Abbreviations: sc= subcutaneous p.r.n.=pro re nata (as needed medication) 
$) a response included immediate (within 4 hours), late (after more than 4 hours) , transient (symptom-free episodes after treatment, but not symptom-free at death) and no response (no symptom-free episode) 
a)  n= number of patients in the intervention group 
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Search strategy  
(Death [mesh] OR death*[tw] OR asphyx*[tw] OR dying [tw] OR terminal*[tw] OR end-of-life [tw]) AND (rattl*[tw] OR 
respiratory sound*[tw] OR respiratory nois*[tw] OR noisy breath*[tw] OR breathing nois*[tw] OR lung sound*[tw] OR 
pleural rub*[tw] OR rhonch*[tw] OR bronchial secret*[tw] OR respiratory secret*[tw] OR respiratory tract secret*[tw]) 
NOT (snake*[tw] OR rattlesnake*[tw] OR rna[tw] OR tobacco rattl*[tw] OR rattle virus[tw]) 
 
Full texts (n=154) 
Abstracts (n=218) 
Articles included (n=36) 
Studies added after hand 
search of reference (n=3) 
 
Papers excluded (n=824) 
- Not about death rattle in dying phase (n=777) 
- Not about adults/ Article about children (n=3) 
- Not about humans / Article about animals (n=5) 
- No original empirical research* (n=4) 
- Language other than English (n=35) 
*Including reviews, comments, case studies, 
letters, conference abstracts 
 
Abstracts excluded (n=84) 
- Not about death rattle in dying phase (n=80) 
- No original empirical research* (n=3) 
- Language other than English (n=1) 
 
Full text excluded (n=118) 
- Not about death rattle in dying phase (n=30) 
- Not about humans / Article about animals (n=3) 
- Study population not sufficient <5/50 (n=1)  
- No original empirical research* (n=73) 
- Language other than English (n=10) 
- Not possible to find full text (n=1) 
 
Articles included (n=39) 
Unique papers (n=1062) 
Figure 1. Search strategy and selection of papers 
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APPENDIX Table 1. Prevalence in subgroups  
 
Author/country/ 
year of publication 
         
Setting Diagnosis 
Sample 
size
a
 Prevalence in subgroups 
 Jakobsson et al
42
., 
Sweden, 2008 
Residential care, 
home care 
Diagnosis not 
specified 
229  Physical function 
 Adl-independent  
 Adl-dependent  
Cognitive function 
 Oriented 
 Disoriented  
 
28% 
32% (p > 0·05) 
 
25% 
41% (p = 0·022) 
 Morita et al
29
., 
Japan, 2005 
Hospital, PCU, 
home care  
Cancer (abdominal) 226  Hydration status 
  Prevalence of secretion score ≥ 1
b
 
 Hydration + 
(c) 
 
 Hydration – 
(d)
 
  Prevalence of secretion score ≥ 2
b
 
 Hydration + 
 Hydration – 
 
 
 
44% 
46% (p > 0·05) 
 
19% 
17% (p > 0·05) 
 Morita et al
28
., 
Japan, 2004 
 
 
Hospital, PCU, 
home care  
Cancer (lung + 
abdominal) 
310  Primary tumor site  
 Abdominal 
 Lung 
Brain metastases 
 Present 
 Absent 
Lung metastases 
 Present  
 Absent  
Pneumonia 
 Present 
 Absent 
Dysphagia 
 Present 
 Absent 
No correlation with age and gender 
 
67% 
46% (p = 0·001) 
 
56% 
51% (p > 0·05) 
 
58% 
47% (p > 0·05) 
 
68% 
46% (p = 0·002) 
 
 
75% 
49% (p > 0·05) 
 Kass et al
43
., UK, 
2003 
PCU Cancer (various 
tumors) 
202  Tumor locations 
 Lung cancer 
 GI cancer 
 Hepatobiliary & pancreatic ca 
 Breast 
 Gynecological cancer - breast  
 Urological, renal & prostatic ca  
 Musculoskeletal & skin cancer  
 Brain cancer  
 Other ca or unknown primary  
 non-cancer 
Risk factors for development 
 Age  
 Male gender 
 Lung cancer 
 
68%  
42%  
40%  
46%   
35%   
29%   
43%   
75%   
50%   
50%   
 
(p > 0·05) 
(p = 0·034) RR 1,35 
(p = 0·003) RR 1·58 
 Morita et al
8
., 
Japan, 2000 
Hospital  Cancer (various 
tumors) 
245  Tumor in brain  
 Present 
 Absent 
Tumor in lung  
 Present  
 Absent  
Tumor in bone 
 Present 
 Absent 
Tumor in liver 
 Present 
 Absent  
Tumor in intestinal tract 
 Present 
 Absent  
 
21% 
9% (p <0·01) 
 
63% 
34% (p < 0·01) 
 
46% 
29% (p < 0·01) 
 
32% 
51% (p<0·01) 
 
27% 
40% (p <0·05) 
 Pautex et al
46
., 
Switserland, 1997 
Hospital  Mixed (cancer and 
various non-cancer) 
100  Dementia 
 Yes 
 No  
 
46% 
30% (p > 0·05) 
 Bennett et a
6
l., UK, 
1996 
Hospice Mixed (long, liver, 
brain tumors, COPD, 
heart failure) 
96  Duration of stay > 9 days 
Cerebral malignancy 
No correlation with pulmonary 
malignancies or pulmonary diseases 
p = 0·048 
p = 0·048 
a)Number of patients in the study on which prevalence was based b) Death rattle score25 : ‘inaudible’ (score 0), ‘audible only very close to the patient’ (score 
1), ‘clearly audible at the end of the bed in a quiet room’ (score 2) and ‘clearly audible at about 6m or at the door of the room’ (score 3)  
c) Artificial hydration ≥ 1 l/day  d) Artificial hydration < 1 l/day 
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